AI & Healthcare Policy
Latest in AI & Healthcare Policy· Nov 11
A clinical analysis found escitalopram more effective than fluoxetine at preventing depression relapse, shifting prescribing patterns toward the already-generic drug. The finding carries limited commercial impact since escitalopram lacks pricing power as an established generic, but influences treatment protocols and competitive positioning for companies developing alternative antidepressants or adjunctive therapies. Patient outcomes in depression management improve with the clearer efficacy data, though the result does not alter the underlying economics of a saturated generic market.
Government officials and health agencies promoting AI adoption in medical practice and healthcare decision-making, raising concerns about clinical judgment and patient safety.
2 events tracked
- Single source2 days ago
Escitalopram beats Prozac at blocking depression relapse
Analysis shows escitalopram and two other antidepressants outperformed Prozac in preventing relapse across a large patient population.
BBC News
- Single sourceabout 1 month ago
Kennedy claims artificial intelligence surpasses physicians in medical knowledge
Robert Kennedy Jr. stated at a health conference that AI possesses superior information compared to doctors, suggesting a potential realignment in medical expertise.
The New York Times